Cnnabidiol (CBD) treatment enhances TREM2 and IL-33 expression, alleviates neurocognitive functional impairment by regulating glial cell function, improves AD symptoms, and inhibits the expression of pro-inflammatory factor (IL-6) in white blood cells (WBCs) in peripheral blood; therefore, CBD treatment can be used in the clinical settings [62,87]. Here, IL33 is linked to Alzheimer disease.